Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc (USA)  

(Public, NASDAQ:MSLI)   Watch this stock  
Find more results for MSLI
0.000 (0.00%)
Oct 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.92 - 1.90
Open     -
Vol / Avg. 0.00/18,699.00
Mkt cap 113.54M
P/E     -
Div/yield     -
EPS -0.07
Shares 116.85M
Beta 1.60
Inst. own 0%
Aug 15, 2016
Q3 2016 Merus Labs International Inc Earnings Release
Aug 15, 2016
Q3 2016 Merus Labs International Inc Earnings Call
Aug 11, 2016
Merus Labs International Inc at Canaccord Genuity Growth Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -19.69% -0.49%
Operating margin -7.22% 12.66%
EBITD margin - 61.48%
Return on average assets -5.35% -0.10%
Return on average equity -10.23% -0.17%
Employees 6 -
CDP Score - -


100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
+1-416-5933701 (Phone)
+1-416-5934434 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Bio & Compensation  - Reuters
Barry Fishman Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael Bumby Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Robert McLay Vice President - Sales and Marketing
Bio & Compensation  - Reuters
Frank Rotmann Vice President and Head of European Operations
Bio & Compensation  - Reuters
Robert Bloch M.D. Director
Bio & Compensation  - Reuters
Theresa Sheila Firestone Independent Director
Bio & Compensation  - Reuters
David D. Guebert CPA Independent Director
Bio & Compensation  - Reuters
Robert S. Pollock Independent Director
Bio & Compensation  - Reuters
Timothy G. Sorensen Independent Director
Bio & Compensation  - Reuters